Skip to Main Content

clinical trials

Drug clinical trial news involving companies such as Intellia, ActiGraph, Light Sciences Oncology, Nektar Therapeutics, Vir and Bellerophon Therapeutics, and drugs such as lecanemab and Wegovy. There’s also coverage of how to increase diversity in pharmaceutical clinical trials, animal welfare in clinical research, and an in-depth story on why a failed clinical trial doesn’t always spell doom for a new drug.

Latest

First Opinion Vijay Ramakrishnan

STAT Plus: How payer-participating trials could help transform clinical research on FDA-approved drugs

Health Nicholas St. Fleur

STAT Virtual Event | How to Increase Diversity in Clinical Trials: Strategies & Tools

First Opinion Rachel King and Peter L. Saltonstall

STAT Plus: The IRA needs changes to better support patients with rare diseases

The Obesity Revolution Elaine Chen, Allison DeAngelis and J. Emory Parker

STAT Plus: Here are the dozens of weight loss drugs in development to catch a booming market

Health Deborah Balthazar

What could fix cancer clinical trials’ longstanding diversity problem?

Biotech Megan Molteni

STAT Plus: Intellia plays down concerns about accidental germline transmission in CRISPR trial

Health Tech Mario Aguilar

STAT Plus: ActiGraph executives on why getting digital endpoints approved for drug trials matters

First Opinion Liz Beatty

The definition of clinical trial diversity must include disabled people

All Coverage

Biotech Erica Goode

STAT Plus: Failed clinical trials don’t always spell doom for a new drug. Here’s why

Pharmalot Ed Silverman

STAT Plus: Nektar Therapeutics sues Lilly for ‘misconduct’ in drug development deal

advertisement

Politics Rachel Cohrs

NIH begins long-delayed clinical trials for long Covid, announces new research office

Pharmalot Ed Silverman

STAT Plus: European Commission accelerates phasing out animal testing, but stops short of a ban

In the Lab Deborah Balthazar

Statins reduce cardiovascular risk in people living with HIV, new global study finds

Biotech Jason Mast

STAT Plus: Vir antibody drug aimed at influenza A fails in clinical trial

In the Lab Bree Iskandar

Doctors use precision medicine to show melanoma drugs can shrink rare brain tumor by 90%

First Opinion Richard Joseph and Rachele Pojednic

How to separate sound wellness solutions from seductive snake oil

First Opinion Christina Lopes and James Zou

STAT Plus: The DNA from dog tumors may hold the secret to better human cancer drugs

First Opinion Jason Karlawish

The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab

STAT Staff

STAT Virtual Event – Decoding Clinical Trials: How to Spot and Avoid Clinical Trial Risk

Health Tech Mario Aguilar

STAT Plus: Bellerophon Therapeutics trial fails despite innovative digital endpoint

First Opinion Gloria Coronado and Leslie Bienen

STAT Plus: An overlooked way to make participants in clinical trials look more like America

Business Andrew Joseph

STAT Plus: U.K. unveils $800 million package to bolster life sciences amid concern over biopharma investments

Pharma Elaine Chen

STAT Plus: In early trial, drug appears to reduce harmful protein buildup in heart

Pharmalot Ed Silverman

STAT Plus: 1 in 5 primary endpoints changed in late-stage trials of cancer drugs already underway, study finds

Health Amanda Loudin

After decades of neglecting women athletes, sport and exercise medicine is finally catching up

Biotech Jason Mast

STAT Plus: Gene therapy death not caused by CRISPR, investigators confirm

Business Alexa Gagosz — Boston Globe

STAT Plus: CVS Health to close clinical trial unit two years after launch

Health Tech Mario Aguilar

STAT Plus: Biotech and pharma execs wrestle with the ‘nightmare’ of developing digital biomarkers

Exclusive Megan Molteni

From fusion to retooling cancer trials, Eric Lander wants his new group to ‘go after big problems’